Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G3139 and Rituximab in Recurrent B-cell NHL
NCT00054639Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2003
- Primary completion
- Jan 2010
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oblimersen in B-cell non-Hodgkin lymphoma, sponsored by National Cancer Institute. Primary endpoint: Number of Patients With Objective Response at 2 months. Started Jan 2003; status: completed.
02
Drugs
oblimersen
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00054639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054639.